Optimizing Regulation and Greeting the Era of Cell Therapy
Department of Immunity, Peking University School of Basic Medicine, Comprehensive Laboratory of Pathogens and Immunity,Biomedical Experimental Teaching Center, Peking University, Key Laboratory of Medical Immunology, National Health Commission, Beijing 100191, China
[1]宋硕,李炜昕,王诚.国内生物治疗监管政策的思考[J].现代医院,2021,21(10):14941497. [2]王刚.细胞和基因治疗产品监管政策的中美比较[J].中国食品药品监管,2019,(8):2025. [3]U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for human somatic cell therapy and gene therapy[J].Hum Gene Ther, 2001, PMID: 11177566 [4]孟淑芳,佑春,吴雪伶,等. CART细胞治疗产品质量控制检测研究及非临床研究考虑要点[J].中国药事,2018,32(6):831852. [5]梅妮,李刚,陈一飞.基因修饰细胞治疗产品及欧盟监管法规介绍[J].上海医药,2021,42(13):1416. [6]赵晓宇,苏岭,杨建红,等.药品监管科学研究之基因和细胞治疗产品Ⅱ:我国监管体系的完善建议[J].中国药事,2021,35(5):516522. [7]U.S. Food and Drug Administration. Bioresearch Monitoring Discipline Review Memo,August 1,2017KYMRIAH[EB/OL]. (20180301) [20220405]. https://www.fda.gov/ biologicsbloodvaccines/ cellulargenetherapyproducts/approvedproducts/. [8]李娜,张晓.韩国细胞治疗产品监管政策及对我国的启示[J].中国新药杂志,2021,30(7):584589. [9]吴曙霞,杨淑娇,吴祖泽.美国、欧盟、日本细胞治疗监管政策研究[J].中国医药生物技术,2016,11(6) :491496. [10]田佳鑫.美国 FDA 对再生医学产品的监管及启示[J].生物技术通讯,2017,28(5):685688. [11]韩倩倩,王春仁.基因治疗产品、细胞治疗产品和组织工程产品在欧盟的监管[J].组织工程与重建外科,2014,10(5):244246. [12]李玉,张晓.日本细胞治疗监管双轨制的经验及启示[J].中国生物工程杂志,2020,40(Z1) : 174179.